Effects of widely used drugs on micronutrients: A story rarely told

Nutrition

Volumn 29, Issue 4, 2013, Pages 605-610

  Samaras, Dimitrios ^a   Samaras, Nikolaos ^a   Lang, Pierre Olivier ^b,c   Genton, Laurence ^a   Frangos, Emilia ^d   Pichard, Claude ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CRANFIELD UNIVERSITY   (United Kingdom)

^c Nescens Centre of Preventive Medicine   (Switzerland)

^d Clinic of Jolimont   (Switzerland)

Author keywords

Adverse effect; Drug interactions; Micronutrient; Trace element; Vitamin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ASCORBIC ACID; CAPTOPRIL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; FOLIC ACID; HAPTOCORRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; METFORMIN; MEVINOLIN; OMEPRAZOLE; PEPSIN A; PROTON PUMP INHIBITOR; TRACE ELEMENT; UBIDECARENONE; VITAMIN; VITAMIN D; ZINC;

ASCORBIC ACID DEFICIENCY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHEMICAL INTERACTION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CYANOCOBALAMIN DEFICIENCY; DIET; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MICRONUTRIENT INTERACTION; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; DRUG URINE LEVEL; DRUG WITHDRAWAL; FOLIC ACID DEFICIENCY; HEART FAILURE; HELICOBACTER INFECTION; HEMOCHROMATOSIS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTESTINE ABSORPTION; IRON ABSORPTION; IRON DEFICIENCY; IRON DEPLETION; KIDNEY TUBULE ABSORPTION; LOW DRUG DOSE; MALABSORPTION; MYALGIA; MYOPATHY; NONHUMAN; NUTRITIONAL DEFICIENCY; NUTRITIONAL PARAMETERS; ORGANOLEPTIC PROPERTY; PATIENT ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; RECOMMENDED DIETARY ALLOWANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ACID; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; ZINC BLOOD LEVEL; ZINC DEFICIENCY; ZINC METABOLISM;

ANIMALS; DEFICIENCY DISEASES; DIETARY SUPPLEMENTS; FOOD-DRUG INTERACTIONS; HUMANS; MICRONUTRIENTS; PRESCRIPTION DRUGS; RISK;

EID: 84875328846     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.11.011     Document Type: Review

References (77)

1. Galan P., Briancon S., Favier A., Bertrais S., Preziosi P., Faure H., et al. Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels?. Br J Nutr 2005, 94:125-132.
2. Dwyer L.L., Han B., Woodwell D.A., Rechtsteiner E.A. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother 2010, 8:63-72.
3. Berger M.M. Chapitre 11: Eléments Traces. Traité de nutrition artificielle de l'adulte 2007, 1189. Springer, Paris. 3rd ed. D.B. Noël Cano, S. Stéphane, V. Marie-Paule, H. Michel, L. Xavier (Eds.).
4. Tiwari A., Bansal V., Chugh A., Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 2006, 5:651-666.
5. Doty R.L., Shah M., Bromley S.M. Drug-induced taste disorders. Drug Saf 2008, 31:199-215.
6. Tsuruoka S., Wakaumi M., Araki N., Ioka T., Sugimoto K., Fujimura A. Comparative study of taste disturbance by losartan and perindopril in healthy volunteers. J Clin Pharmacol 2005, 45:1319-1323.
7. Tomita H., Yoshikawa T. Drug-related taste disturbances. Acta Otolaryngol Suppl 2002, 546:116-121.
8. Abu-Hamdan D.K., Desai H., Sondheimer J., Felicetta J., Mahajan S., McDonald F. Taste acuity and zinc metabolism in captopril-treated hypertensive male patients. Am J Hypertens 1988, 1:303S-308S.
9. Golik A., Zaidenstein R., Dishi V., Blatt A., Cohen N., Cotter G., et al. Effects of captopril and enalapril on zinc metabolism in hypertensive patients. J Am Coll Nutr 1998, 17:75-78.
10. Koren-Michowitz M., Dishy V., Zaidenstein R., Yona O., Berman S., Weissgarten J., et al. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. Am J Hypertens 2005, 18:358-363.
11. Tubek S. Zinc balance normalization: an important mechanism of angiotensin-converting enzyme inhibitors and other drugs decreasing the activity of the rennin-angiotensin-aldosterone system. Biol Trace Elem Res 2007, 115:223-226.
12. Golik A., Cohen N., Ramot Y., Maor J., Moses R., Weissgarten J., et al. Type II diabetes mellitus, congestive heart failure, and zinc metabolism. Biol Trace Elem Res 1993, 39:171-175.
13. Prasad A.S., Fitzgerald J.T., Hess J.W., Kaplan J., Pelen F., Dardenne M. Zinc deficiency in elderly patients. Nutrition 1993, 9:218-224.
14. Cohen N., Golik A. Zinc balance and medications commonly used in the management of heart failure. Heart Fail Rev 2006, 11:19-24.
15. Sahud M.A., Cohen R.J. Effect of aspirin ingestion on ascorbic-acid levels in rheumatoid arthritis. Lancet 1971, 1:937-938.
16. Schulz H.U., Schurer M., Krupp S., Dammann H.G., Timm J., Gessner U. Effects of acetylsalicylic acid on ascorbic acid concentrations in plasma, gastric mucosa, gastric juice and urine-a double-blind study in healthy subjects. Int J Clin Pharmacol Ther 2004, 42:481-487.
17. Basu T.K. Vitamin C-aspirin interactions. Int J Vitam Nutr Res Suppl 1982, 23:83-90.
18. Loh H.S., Watters K., Wilson C.W. The effects of aspirin on the metabolic availability of ascorbic acid in human beings. J Clin Pharmacol 1973, 13:480-486.
19. Batuwitage B.T., Kingham J.G., Morgan N.E., Bartlett R.L. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007, 83:66-68.
20. Festen H.P. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl 1991, 188:1-7.
21. Saltzman J.R., Kemp J.A., Golner B.B., Pedrosa M.C., Dallal G.E., Russell R.M. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr 1994, 13:584-591.
22. Kittang E., Aadland E., Schjonsby H. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut 1985, 26:594-598.
23. Marcuard S.P., Albernaz L., Khazanie P.G. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994, 120:211-215.
24. Schenk B.E., Festen H.P., Kuipers E.J., Klinkenberg-Knol E.C., Meuwissen S.G. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996, 10:541-545.
25. den Elzen W.P., Groeneveld Y., de Ruijter W., Souverijn J.H., le Cessie S., Assendelft W.J., et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008, 27:491-497.
26. Dharmarajan T.S., Kanagala M.R., Murakonda P., Lebelt A.S., Norkus E.P. Do acid-lowering agents affect vitamin B12 status in older adults?. J Am Med Dir Assoc 2008, 9:162-167.
27. Valuck R.J., Ruscin J.M. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57:422-428.
28. Pennypacker L.C., Allen R.H., Kelly J.P., Matthews L.M., Grigsby J., Kaye K., et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992, 40:1197-1204.
29. Kuipers E.J., Lundell L., Klinkenberg-Knol E.C., Havu N., Festen H.P., Liedman B., et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996, 334:1018-1022.
30. Labenz J., Tillenburg B., Peitz U., Idstrom J.P., Verdu E.F., Stolte M., et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996, 110:725-732.
31. Schenk B.E., Kuipers E.J., Klinkenberg-Knol E.C., Bloemena E.C., Sandell M., Nelis G.F., et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther 1999, 13:1343-1346.
32. Sagar M., Janczewska I., Ljungdahl A., Bertilsson L., Seensalu R. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther 1999, 13:453-458.
33. Mirvish S.S., Wallcave L., Eagen M., Shubik P. Ascorbate-nitrite reaction: possible means of blocking the formation of carcinogenic N-nitroso compounds. Science 1972, 177:65-68.
34. McColl K.E. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009, 104(suppl 2):S5-S9.
35. Woodward M., Tunstall-Pedoe H., McColl K. Helicobacter pylori infection reduces systemic availability of dietary vitamin C. Eur J Gastroenterol Hepatol 2001, 13:233-237.
36. Mowat C., Carswell A., Wirz A., McColl K.E. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology 1999, 116:813-822.
37. Mowat C., Williams C., Gillen D., Hossack M., Gilmour D., Carswell A., et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 2000, 119:339-347.
38. Henry E.B., Carswell A., Wirz A., Fyffe V., McColl K.E. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther 2005, 22:539-545.
39. Ito T., Jensen R.T. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010, 12:448-457.
40. Sharma V.R., Brannon M.A., Carloss E.A. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004, 97:887-889.
41. Sarzynski E., Puttarajappa C., Xie Y., Grover M., Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011, 56:2349-2353.
42. Hutchinson C., Geissler C.A., Powell J.J., Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007, 56:1291-1295.
43. Sasazuki S., Sasaki S., Tsubono Y., Okubo S., Hayashi M., Kakizoe T., et al. The effect of 5-year vitamin C supplementation on serum pepsinogen level and Helicobacter pylori infection. Cancer Sci 2003, 94:378-382.
44. Kuzminski A.M., Del Giacco E.J., Allen R.H., Stabler S.P., Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998, 92:1191-1198.
45. Kooy A., de Jager J., Lehert P., Bets D., Wulffele M.G., Donker A.J., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009, 169:616-625.
46. Kos E., Liszek M.J., Emanuele M.A., Durazo-Arvizu R., Camacho P. Effect of metformin therapy on vitamin D and vitamin B12 levels in patients with type 2 diabetes mellitus. Endocr Pract 2012, 18:179-184.
47. de Jager J., Kooy A., Lehert P., Wulffele M.G., van der Kolk J., Bets D., et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010, 340:c2181.
48. Wulffele M.G., Kooy A., Lehert P., Bets D., Ogterop J.C., Borger van der Burg B., et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003, 254:455-463.
49. Ting R.Z., Szeto C.C., Chan M.H., Ma K.K., Chow K.M. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 2006, 166:1975-1979.
50. Bauman W.A., Shaw S., Jayatilleke E., Spungen A.M., Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000, 23:1227-1231.
51. Andres E., Federici L. Vitamin B12 deficiency in patients receiving metformin: clinical data. Arch Intern Med 2007, 167:729. author reply 30-1.
52. Callaghan T.S., Hadden D.R., Tomkin G.H. Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment. Br Med J 1980, 280:1214-1215.
53. Bell D.S. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 2010, 103:265-267.
54. Statins: The World Market, 2009-2024 2009, Visiongain, Ltd, London, UK.
55. Harper C.R., Jacobson T.A. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010, 12:322-330.
56. Joy T.R., Hegele R.A. Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858-868.
57. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414.
58. Crane F.L. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001, 20:591-598.
59. James A.M., Smith R.A., Murphy M.P. Antioxidant and prooxidant properties of mitochondrial Coenzyme Q. Arch Biochem Biophys 2004, 423:47-56.
60. Arroyo A., Navarro F., Gomez-Diaz C., Crane F.L., Alcain F.J., Navas P., et al. Interactions between ascorbyl free radical and coenzyme Q at the plasma membrane. J Bioenerg Biomembr 2000, 32:199-210.
61. Constantinescu A., Maguire J.J., Packer L. Interactions between ubiquinones and vitamins in membranes and cells. Mol Aspects Med 1994, 15(suppl):s57-s65.
62. Sacconi S., Trevisson E., Salviati L., Ayme S., Rigal O., Redondo A.G., et al. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010, 20:44-48.
63. Grunler J., Ericsson J., Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1994, 1212:259-277.
64. Paiva H., Thelen K.M., Van Coster R., Smet J., De Paepe B., Mattila K.M., et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005, 78:60-68.
65. Laaksonen R., Jokelainen K., Laakso J., Sahi T., Harkonen M., Tikkanen M.J., et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996, 77:851-854.
66. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., Himberg J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995, 57:62-66.
67. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231-2237.
68. Lamperti C., Naini A.B., Lucchini V., Prelle A., Bresolin N., Moggio M., et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005, 62:1709-1712.
69. Mori T.A., Burke V., Puddey I., Irish A., Cowpland C.A., Beilin L., et al. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens 2009, 27:1863-1872.
70. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2:483-491.
71. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
72. Muir S.W., Montero-Odasso M. Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2011, 59:2291-2300.
73. Bischoff-Ferrari H.A., Dawson-Hughes B., Platz A., Orav E.J., Stahelin H.B., Willett W.C., et al. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. Arch Intern Med 2010, 170:813-820.
74. Ahmed W., Khan N., Glueck C.J., Pandey S., Wang P., Goldenberg N., et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009, 153:11-16.
75. Glueck C.J., Budhani S.B., Masineni S.S., Abuchaibe C., Khan N., Wang P., et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 2011, 27:1683-1690.
76. Linde R., Peng L., Desai M., Feldman D. The role of vitamin D and SLCO1B1*;5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol 2010, 2:77-84.
77. Kurnik D., Hochman I., Vesterman-Landes J., Kenig T., Katzir I., Lomnicky Y., et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf) 2012, 77:36-41.